Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$104.30
+0.6%
$103.42
$71.88
$107.53
$154.34B0.686.66 million shs2.93 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$82.73
-1.0%
$83.26
$57.52
$117.19
$32.52B1.444.40 million shs1.84 million shs
Stryker Corporation stock logo
SYK
Stryker
$392.00
+0.0%
$382.92
$314.93
$406.19
$150.87B0.911.35 million shs536,295 shs
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$135.50
+0.1%
$134.16
$127.35
$159.64
$34.68B0.78.80 million shs7.28 million shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Boston Scientific Corporation stock logo
BSX
Boston Scientific
+0.70%-0.36%+1.10%+16.17%+37.03%
DexCom, Inc. stock logo
DXCM
DexCom
-1.02%-2.72%-4.68%+38.28%-25.41%
Stryker Corporation stock logo
SYK
Stryker
+0.01%+0.34%+2.80%+13.25%+18.05%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
+0.10%+0.95%+1.86%+0.16%-5.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Boston Scientific Corporation stock logo
BSX
Boston Scientific
4.5919 of 5 stars
3.63.00.04.22.42.51.3
DexCom, Inc. stock logo
DXCM
DexCom
4.8938 of 5 stars
3.55.00.04.72.82.51.9
Stryker Corporation stock logo
SYK
Stryker
4.6376 of 5 stars
2.43.03.34.23.02.51.3
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Boston Scientific Corporation stock logo
BSX
Boston Scientific
3.13
Buy$116.0911.31% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.95
Moderate Buy$98.5019.06% Upside
Stryker Corporation stock logo
SYK
Stryker
2.79
Moderate Buy$427.309.00% Upside
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
2.69
Moderate Buy$135.50N/A

Current Analyst Ratings Breakdown

Latest SYK, BSX, DXCM, and XLV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/16/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$118.00
6/16/2025
DexCom, Inc. stock logo
DXCM
DexCom
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$102.00
5/30/2025
DexCom, Inc. stock logo
DXCM
DexCom
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$104.00
5/28/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$115.00
5/22/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$119.00 ➝ $125.00
5/22/2025
DexCom, Inc. stock logo
DXCM
DexCom
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$82.00 ➝ $102.00
5/22/2025
Stryker Corporation stock logo
SYK
Stryker
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$443.00 ➝ $455.00
5/16/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$120.00 ➝ $125.00
5/8/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/5/2025
Stryker Corporation stock logo
SYK
Stryker
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$450.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$16.75B9.21$3.65 per share28.58$14.93 per share6.99
DexCom, Inc. stock logo
DXCM
DexCom
$4.03B8.04$2.24 per share36.90$5.38 per share15.38
Stryker Corporation stock logo
SYK
Stryker
$22.60B6.62$14.96 per share26.21$54.13 per share7.24
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$1.85B$1.3776.1332.292.7111.58%18.67%10.38%7/23/2025 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$576.20M$1.3461.7433.631.7712.90%30.05%10.00%7/24/2025 (Estimated)
Stryker Corporation stock logo
SYK
Stryker
$2.99B$7.4052.9726.432.9812.31%23.74%11.25%7/29/2025 (Estimated)
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/A21.15N/AN/AN/AN/AN/A

Latest SYK, BSX, DXCM, and XLV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2025Q2 2025
Stryker Corporation stock logo
SYK
Stryker
$3.06N/AN/AN/A$5.92 billionN/A
7/24/2025Q2 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.45N/AN/AN/A$1.13 billionN/A
7/23/2025Q2 2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$0.72N/AN/AN/A$4.89 billionN/A
5/1/2025Q1 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.33$0.32-$0.01$0.27$1.02 billion$1.04 billion
5/1/2025Q1 2025
Stryker Corporation stock logo
SYK
Stryker
$2.73$2.84+$0.11$1.69$5.68 billion$5.87 billion
4/23/2025Q1 2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$0.67$0.75+$0.08$0.45$4.57 billion$4.66 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Boston Scientific Corporation stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Stryker Corporation stock logo
SYK
Stryker
$3.360.86%N/A45.41%32 Years
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$2.391.76%N/AN/AN/A

Latest SYK, BSX, DXCM, and XLV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/8/2025
Stryker Corporation stock logo
SYK
Stryker
quarterly$0.840.88%6/30/20256/30/20257/31/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.47
1.45
0.88
DexCom, Inc. stock logo
DXCM
DexCom
0.55
1.50
1.32
Stryker Corporation stock logo
SYK
Stryker
0.69
1.64
1.00
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Boston Scientific Corporation stock logo
BSX
Boston Scientific
89.07%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Stryker Corporation stock logo
SYK
Stryker
77.09%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/A

Insider Ownership

CompanyInsider Ownership
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.50%
DexCom, Inc. stock logo
DXCM
DexCom
0.32%
Stryker Corporation stock logo
SYK
Stryker
5.90%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Boston Scientific Corporation stock logo
BSX
Boston Scientific
53,0001.48 billion1.47 billionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
10,300392.11 million390.85 millionOptionable
Stryker Corporation stock logo
SYK
Stryker
53,000381.69 million359.17 millionOptionable
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/A256.22 millionN/ANot Optionable

Recent News About These Companies

6 ETFs to Invest in June
Healthcare ETFs Slide as UnitedHealth Plunges
Young woman doctor holding a tablet pc — Photo
Top Analyst-Rated Healthcare Stocks to Watch Now (XLV)
...
SPDR Health Care Select Sector (XLV)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Boston Scientific stock logo

Boston Scientific NYSE:BSX

$104.30 +0.67 (+0.64%)
Closing price 07/3/2025 03:59 PM Eastern
Extended Trading
$104.30 0.00 (0.00%)
As of 07/3/2025 04:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

DexCom stock logo

DexCom NASDAQ:DXCM

$82.73 -0.85 (-1.02%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$82.87 +0.14 (+0.17%)
As of 07/3/2025 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Stryker stock logo

Stryker NYSE:SYK

$392.00 +0.19 (+0.05%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$394.48 +2.47 (+0.63%)
As of 07/3/2025 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

Health Care Select Sector SPDR Fund stock logo

Health Care Select Sector SPDR Fund NYSEARCA:XLV

$135.50 +0.14 (+0.10%)
Closing price 07/3/2025 05:00 PM Eastern
Extended Trading
$135.49 -0.01 (-0.01%)
As of 07/3/2025 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager.